Sequential method for determining the 95% effective dose of esketamine for nasal sedation in pediatric dental caries examination

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200058047

Enrollment

Unknown

Registered

2022-03-27

Start date

2022-05-06

Completion date

Unknown

Last updated

2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Dental Anxiety

Interventions

Experimental group:Midazolam oral liquid 0.5 mg/kg, esketamine sequential dosing

Eligibility

Sex/Gender

All

Age

2 Years to 6 Years

Inclusion criteria

Inclusion criteria: Children aged 2 to 6 years who are scheduled to be sedated for dental caries and have American Society of Anesthesiologists (ASA) body status I to II.

Exclusion criteria

Exclusion criteria: 1. Without consent; 2. Allergy to midazolam oral solution, Esketamine, runny nose (i.e. runny nose), kidney or liver dysfunction, any serious systemic illness, or fever.

Design outcomes

Primary

Measure	Time frame
95% effective dose;	—

Countries

China

Contacts

Public ContactYu Cong

500158@hospital.cqmu.edu.cn+86 13996202110

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026